Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024
Cash flows from operating activities:
Net loss	$ (7,640)	$ (6,436)	$ (4,319)	$ (4,970)	$ (14,076)	$ (9,289)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	29		31		59	63
Stock-based compensation					902	946
Change in fair value of warrant liability	(9,609)		(1,696)		(18,663)	(3,151)
Loss on issuance of warrant liabilities	10,352		0		18,150	0
Operating lease, net					116	108
Transaction costs allocated to warrant liabilities					2,995	0
Changes in operating assets and liabilities:
Prepaid expenses and other assets					(1,503)	(163)
Accounts payable					1,526	335
Accrued expenses and other current liabilities					348	(1,515)
Net cash used in operating activities					(10,146)	(12,666)
Cash flows from investing activities:
Purchase of fixed assets					0	(13)
Net cash used in investing activities					0	(13)
Cash flows from financing activities:
Proceeds from exercise of warrants					10	0
Payment of tax liability for vested restricted stock units					0	(25)
Proceeds from sale of common stock, pre-funded and common warrants and warrant inducement, net of issuance and transaction costs					13,412	0
Net cash provided by (used in) financing activities					13,422	(25)
Effect of exchange rate changes on cash and cash equivalents					3	(1)
Net increase (decrease) in cash and cash equivalents					3,279	(12,705)
Cash and cash equivalents, - beginning of period		$ 4,278		$ 23,550	4,278	23,550	$ 23,550
Cash and cash equivalents, - end of period	$ 7,557		$ 10,845		7,557	10,845	$ 4,278
Non-cash investing and financing activities:
Transaction costs related to the sale of common stock, pre-funded and common warrants					584	0
Offering costs included in accounts payable and accrued liabilities					$ 553	$ 0